Biohaven announces leadership changes as Car retires, Pirman promoted
Biohaven's chief scientific officer moves to a new part-time innovation role while David Pirman takes over discovery operations, effective July 13, 2026.
Biohaven Ltd. (NYSE: BHVN) disclosed scientific leadership transitions in an 8-K filed July 9, 2026. On July 9, 2026, Biohaven Ltd. and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer.1
In his new position, as Chief Innovation Officer, Dr. Car will focus on advancing Biohaven's scientific initiatives and external collaborations, including leading multiple assets under the Company's collaboration with Bexorg, Inc.1 Dr. Car will continue to serve as an executive officer of the Company.1 In connection with his transition to a part-time role, Dr. Car's salary will be reduced by fifty percent (50%) to reflect his work schedule.1
In connection with this transition, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, effective July 13, 2026, and will lead the Company's internal drug-discovery organization, overseeing research programs.1
The filing also noted a separate governance update. Warren Volles, General Counsel and Chief Legal Officer, has also been designated an executive officer of Biohaven and will continue to lead the Company's legal function.1
The company stated there were no related arrangements tied to the changes. There are no arrangements or understandings between Dr. Car and any other persons pursuant to which he agreed to transition to a part-time role.1 There are no related party transactions between Dr. Car and the Company that would require disclosure under Item 401(a) of Regulation S-K.1
Background on the collaboration referenced in the filing: in June 2025, Biohaven and Bexorg, Inc., a New Haven-based techbio company, announced a multi-program research collaboration to identify, de-risk, and advance next-generation therapies for CNS disorders, using Bexorg's whole-brain discovery platform to demonstrate target engagement in relevant cell types and tissues and to generate biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data supporting Biohaven preclinical programs.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.